Business Profile & Competitive Position
AMETEK, Inc. operates in the Industrials sector under the Electrical Equipment & Parts industry. It is a global manufacturer of electronic instruments and electromechanical devices, organized into two operating groups: Electronic Instruments (EIG) and Electromechanical (EMG). EIG designs and manufactures advanced analytical, test, and measurement instruments for process, aerospace, power, and industrial markets. EMG supplies precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals, and electrical interconnects to aerospace and defense, medical, automation, and other industrial markets.
The headline profitability metrics are a 20.0% net margin and a 14.5% return on equity. In an industrial-components setting, those figures point toward disciplined execution, pricing power in specification-critical applications, and efficient capital management. The portfolio’s mix of recurring aftermarket instruments and long-cycle OEM components also supports relatively stable revenue, though the available data alone do not prove an unassailable economic moat.
Financial Posture
AMETEK currently carries a market capitalization of $55.3 billion and a trailing price-to-earnings ratio of 35.1. That multiple is a clear premium to many industrial peers and suggests the market is paying up for consistency rather than screening for deep value. The premium is partially underpinned by a 20.0% net margin, which gives management substantial room to generate cash, and a 14.5% ROE, which indicates acceptable returns on book equity.
Beta is 0.96, implying roughly market-level systematic risk. The current share price is $241.12, sitting just below the 50-day exponential moving average of $244.80, while the RSI of 44.1 puts the near-term technical setup in neutral territory. No debt or leverage statistics were included in the supplied data, but the margin and return profile do not point to acute balance-sheet stress.
Strategic Priorities & Outlook
AMETEK’s most recent 10-K filing describes a Growth Model built on four targets: high-single-digit annual sales growth, double-digit annual EPS growth, strong cash flow generation, and a superior return on total capital. To reach those targets, the company focuses on operational excellence through lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization, and artificial intelligence.
Acquisitions are the other major lever. From 2021 through December 31, 2025, AMETEK completed 15 acquisitions representing approximately $1.8 billion in annualized sales. In 2025 alone, it spent $933.2 million—net of cash acquired—to acquire Kern (high-precision machining and optical inspection solutions) and FARO Technologies (3D measurement and imaging solutions). Global expansion is also explicit: AMETEK maintains best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico, and Serbia to stay close to customers and support international growth.
For fiscal year 2025, AMETEK reported sales of $7,401.1 million, up 6.6% from 2024, and diluted earnings per share of $6.40, up 7.9%. The company also posted record operating income, net income, orders, and backlog. Geography matters: 52% of EIG net sales and 42% of EMG net sales went to customers outside the United States, and the company employed approximately 22,500 people as of December 31, 2025.
Macro & Geopolitical Exposure
As an Electrical Equipment & Parts business with global operations, AMETEK carries the standard Industrials macro risks. With roughly half of EIG sales and more than 40% of EMG sales outside the United States, foreign-exchange translation and cross-border tariffs are relevant variables. Its manufacturing footprint in China, Czechia, Malaysia, Mexico, and Serbia means trade policy, logistics costs, and regional regulatory shifts can affect both cost structures and market access.
Aerospace, defense, medical, and automation end markets make the company sensitive to industrial capital expenditure cycles, defense budget trajectories, and medical-device regulatory standards. Commodity inputs—especially specialty metals and electrical components—can move margins, and constraints in semiconductor availability or rare-earth supply chains could ripple through electromechanical production. Currency swings also matter: a stronger U.S. dollar reduces the reported value of foreign revenue, while a weaker dollar has the opposite effect.
Recent Developments
Headline attention intensified as AMETEK approached its November 3, 2026 before-open report. On October 29, 2026, zacks.com published “Unlocking Q3 Potential of Ametek (AME): Exploring Wall Street Estimates for Key Metrics.” Two days earlier, on October 27, 2026, zacks.com ran “Ametek (AME) Earnings Expected to Grow: Should You Buy?” while defenseworld.net reported that Citizens Financial Group Inc. RI purchased 5,502 shares of AMETEK, Inc. (AME). Earlier in the month, on October 15, 2026, zacks.com asked, “Is AMETEK (AME) Outperforming Other Computer and Technology Stocks This Year?” These items point to elevated analyst and institutional scrutiny but are media framing rather than directional signals.
Earnings Behavior & Post-Earnings Drift
AMETEK has beaten earnings estimates in all eight of the most recently reported quarters, a 100% beat rate. The average earnings surprise over that stretch is 4%. Despite the perfect beat streak, the average 5-day price move in the sessions after earnings is just 0.46%, classified as “flat” drift. That disconnect is analytically important: steady outperformance appears to be well anticipated, leaving limited residual momentum in either direction.
The last four reports illustrate the pattern. On August 4, 2026, AMETEK delivered EPS of $2.09 against an estimate of $1.99, a 5.0% surprise; the stock rose 0.28% the next session and 0.89% over the following five days. On April 30, 2026, EPS of $1.97 beat the $1.90 estimate by 3.7%, yet the stock fell 2.13% the next day and 0.33% over five sessions. On February 3, 2026, a 3.6% beat ($2.01 vs. $1.94) produced a next-day decline of 0.48% but a five-day gain of 1.83%. On October 30, 2025, a 7.4% beat ($1.89 vs. $1.76) drove a 1.91% next-day pop, only to see a five-day drift of -0.54%.
The market’s real expectation for the upcoming November 3, 2026 report currently centers on EPS of $2.11, with the stock at $241.12 and the 50-day EMA at $244.80. The historical record says beats have been the norm, but post-release price reactions have been modest and two-way; the real analytical focus is whether the magnitude and guidance can exceed what is already embedded.
Frequently Asked Questions
What are AMETEK's two operating groups?
AMETEK operates through Electronic Instruments (EIG), which designs analytical, test, and measurement instruments, and Electromechanical (EMG), which supplies precision motion control, medical components, thermal management systems, specialty metals, and electrical interconnects.
What is AMETEK's earnings beat rate over the last eight quarters?
AMETEK has beaten earnings estimates in all eight of the most recently reported quarters, a 100% beat rate, with an average surprise of 4%.
What does the stock typically do after AMETEK reports earnings?
Despite the consistent beats, the average 5-day post-earnings price move is only 0.46%, classified as flat drift. Individual quarters have produced a mix of small gains and small losses.
For a more complete picture—covering sell-side ratings, forward estimates, institutional ownership trends, and the broader sector view—investors should consult the full institutional verdict on AMETEK rather than relying on this educational snapshot alone.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-04 | $2.09 | $1.99 | +5% | +0.28% | +0.89% |
| 2026-04-30 | $1.97 | $1.9 | +3.7% | -2.13% | -0.33% |
| 2026-02-03 | $2.01 | $1.94 | +3.6% | -0.48% | +1.83% |
| 2025-10-30 | $1.89 | $1.76 | +7.4% | +1.91% | -0.54% |
| 2025-07-31 | $1.78 | $1.69 | +5.3% | - | - |
| 2025-05-01 | $1.75 | $1.69 | +3.6% | - | - |
Previous AME editions
Get the institutional verdict on AME
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the AME verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.